1 / 24

Paul Morgan, Angharad Morgan, Caroline O’Hagan, Samuel Touchard

Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease work package 3: immune system biomarkers in AD progress update – 30/10/15. Paul Morgan, Angharad Morgan, Caroline O’Hagan, Samuel Touchard. Complement.

amumford
Download Presentation

Paul Morgan, Angharad Morgan, Caroline O’Hagan, Samuel Touchard

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Diseasework package 3: immune system biomarkers in ADprogress update – 30/10/15 Paul Morgan, Angharad Morgan, Caroline O’Hagan, Samuel Touchard

  2. Complement • The complement system is a pivotal part of the immune system and inflammatory processes • The complement system is kept under tight control by soluble and membrane-bound regulators • Balance between complement activation and inhibition • Dysregulation of this balance may contribute to neuroinflammationand disease • Complement activation has been shown to occur in the AD brain, even at very early stages of the disease • Genetic studies have identified AD-associated variants in complement pathway genes

  3. Study design • AD versus control • MCI versus control • MCI progression to AD versus non-progressors • MCI/AD correlation/prediction of rate of decline • Add value to structural imaging

  4. Samples Total = 1147 ADC = 367, MCI =268, CTL =512 Dementia case register n=427 Addneuromed n=720 Still waiting for samples to arrive…. Available data: - Demographics - Cognitive measures - MRI data - Proteomics data

  5. Assays MSD Assay set 1 C3, C4, C5, Fh, fB, fI Assay set 2 C5a, TCC, Bb, C3a, iC3b, fD ELISA Properdin, FHR, C1 inhibitor, CR1, CR2, C1q, CLU, C9

  6. TREM2 • Rare variants in TREM2 increase susceptibility to AD, with an odds ratio similar to that of the apolipoprotein E4 • The encoded protein functions in immune response and may be involved in chronic inflammation by triggering the production of constitutive inflammatory cytokines • TREM2 expression is upregulated in the brain of patients with AD • Measurement of TREM2 protein levels in CSF reported at Alzheimer's Association International Conference 2015 • 2 studies, both reported increased TREM2 in AD

  7. Pump priming award/ARUK network centre grant. • Better monoclonal antibodies against mouse and human TREM-2. • Wild-type mice will be immunised with recombinant soluble human TREM-2 and hybridomas developed using standard techniques. TREM-2 reactive clones will be identified by screening on recombinant protein and on cells expressing TREM-2. Positives will be subcloned to monoclonality. • TREM-2 knockout mice will be immunised with recombinant soluble mouse TREM-2 and hybridomas generated and screened as above and on wild-type and knockout leukocytes.

  8. Additional samples 99 plasma samples Measure: CR1, CLU, C9, C1 inhibitor, TCC

  9. Future work • Other markers • Variant-specific assays – DH variants, FB variants, C3 variants • Other inflammatory markers - Cytokines, Chemokines, MMPs • Other sample sets • Longitudinal samples • Link to structural imaging, genetics and other available datasets • Multivariate methods to arrive at highly predictive algorithms for early diagnosis, stratification, prediction of progression, response to therapy

  10. SchizophreniaMaja Kopczynska

  11. Inflammation and Schizophrenia • Increased levels of IL-6, IL-12, CRP in Schizophrenia patients • Maternal immune activation disrupts normal foetal brain development • Anti-inflammatory medication reduce the coresymptoms of schizophrenia

  12. Complement and Schizophrenia • Complement system may play a role in neurogenesis, synapse remodelling and pruning during brain development • Glial atrophy or reduced cortical glial may contribute to synaptic abnormalities and impaired connectivity in schizophrenia

  13. Methods • Patients and controls from “Stress + Psychosis Study 55516” and “Pump Study 55541” from King’s College Hospital in London • Sample volumes varied between 0.2 – 0.5 ml serum, all samples stored at -30°C since date of collection to arrival to Cardiff, currently stored at -80°C • 228 samples in total were tested in groups of 38 samples per plate for the presence of 16 complement markers • ELISA – 11 markers • C3, C4, C5, C1q, TCC, Factor B, Factor H, FHR, Properdin, C1 inh, CR1 • MSD – 5 markers • Bb, C4d, C5a, iC3b, TCC

  14. Results 156 patients: 25 controls and 131 cases

  15. Analysis • Logistic regression : • Regression model where the dependent variable is binary: 0 or 1 • It studies the relationship between this binary response and different predictors or independent variables, either continuous or categorical • It predicts the odds or probabilities that a sample or observation is a case, based on the values of the predictors • Extensions: multinomial logistic regression and ordinal logistic regression

  16. Summary of the complete model with the 11 analytes Significant predictors: C5 and C1inh at 0.05 CR1 and FH at 0.1

  17. Reduced model computed by stepwise selection Analytes selected: CR1, TCC, C3, C5, C1inh, FH

  18. ROC Curve Area under the curve: 0.85 Area under the curve when only gender is studied: 0.73 Area under the curve when only the assays are studied: 0.77

  19. Predicted probabilities for values of CR1, C1inh, C5 and age

  20. Predicted probabilities for values of C1 inhibitor

  21. Furtherwork • Polish the analysis by dealingwithsomemissing values • Recalibrate to correct absolute values • Explore furtherthissubset of assays, as interactions betweenanalytesalsoseem to have a greatereffect on schizophrenia

  22. Further work on AD data • Classification(s): AD vs Control, MCI vs Control, convertors vs non-convertors... • Logistic regressions: standard or multinomial • Supervised learning: Random forest, Naive Bayes Simple, k- nearest neighbors... • Unsupervised learning: clustering • Cognitive decline: • Linear mixed models with longitudinal scores • Classification methods if the decline or deterioration can be graded in classes or groups

  23. References • Sattlecker et al., Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer and Dementia, 10(6):724-34, 2014 • Hye et al., Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer and Dementia, 10(6):799-807.e2, 2014 • Khan et al., A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. PLoS One, 10(8):e0134368, 2015

More Related